eResearchTechnology Confirms That it Will Meet or Exceed Fourth Quarter and 2004 Guidance

eResearchTechnology Confirms That it Will Meet or Exceed Fourth Quarter and 2004
Guidance 


PHILADELPHIA, Nov. 11  /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. 
reaffirms its guidance for the remainder of 2003 and 2004.  It expects to report
fourth quarter revenues for the quarter ended December 31, 2003 of $18.7 to
$19.0 million and earnings of $0.19 to $0.20 per diluted share.  For the full
year of 2003, it expects revenues of $64.5 to $64.8 million and expects diluted
earnings per share of $0.57 to $0.58.  eRT expects to report revenues of $99 to
$101 million and earnings of $1.02 to $1.05 per diluted share for 2004.  The
guidance does not include the impact of the 3-for-2 stock split previously
announced.  The company will issue one additional share of common stock for
every two shares held by holders of record at the close of business on November
5, 2003.  Cash will be paid in lieu of fractional shares.  The shares will be
distributed on November 26, 2003.

"Management of eRT is confident in its ability to meet or exceed its current
guidance," said Joseph Esposito, eRT's president and chief executive officer. 
"Despite diversification of shares by members of our board and executive
management team, including myself, we remain confident about the company's
future prospects."  The company reported total direct and indirect holdings of
its directors and executive officers at more than 4 million shares of the
company's common stock, including vested and unvested options, which is 65% of
their original holdings prior to any 2003 sales.

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis.  The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development.  The company is
also a leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection, analysis,
and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. 
Such statements, including, but not limited to, 2003 and 2004 guidance, involve
a number of risks and uncertainties such as competitive factors, technological
development, market demand, and the company's ability to obtain new contracts
and accurately estimate net revenues due to variability in size, scope and
duration of projects, and internal issues in the sponsoring client.  As a
result, actual results may differ materially from any financial outlooks stated
herein.  Further information on potential factors that could affect the
company's financial results can be found in the company's Reports on Form 10-K
and 10-Q filed with the Securities and Exchange Commission. 

DATASOURCE: eResearchTechnology, Inc.



CONTACT:  Bruce Johnson, eResearchTechnology, Inc., [phone]; or

Matt Hayden, Hayden Communications, [phone], for eResearchTechnology,

Inc.



Web site:  http://www.ert.com/ 

Copyright